RNS Number : 0890T
BSF Enterprise PLC
15 March 2023

15 March 2023

BSF Enterprise PLC

("BSF" or the "Company")

Result of Annual General Meeting

BSF Enterprise (LSE: BSFA), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that at the Company's Annual General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows:

Resolution		Poll Results				
		For	Against	Abstain	Discretionary	Total
1	Shares	50,625,257	-	-	-	50,625,257
	%	100%	-	-	-	100%
2	Shares	50,596,092	29,165	-	-	50,625,257
	%	99.94%	0.06%	-	-	100%
3	Shares	50,596,092	29,165	-	-	50,625,257
	%	99.94%	0.06%	-	-	100%
4	Shares	48,471,538	-	2,153,719	-	50,625,257
	%	95.75%	-	4.25%	-	100%
5	Shares	50,596,092	-	29,165	-	50,625,257
	%	99.94%	-	0.06%	-	100%
6	Shares	50,596,092	29,165	-	-	50,625,257
	%	99.94%	0.06%	-	-	100%
7	Shares	50,596,092	-	29,165	-	50,625,257
	%	99.94%	-	0.06%	-	100%

For further enquiries, please visit **www.bsfenterprise.com** or contact:

BSF Enterprise PLC — Via SEC Newgate below
Geoff Baker - Non-Executive Director
Che Connon - Executive Director

Shard Capital (Broker)
Damon Heath — 0203 971 7000

SEC Newgate (Financial Communications)
Bob Huxford — 020 3757 6882
Elisabeth Cowell — BSF@secnewgate.co.uk
George Esmond

ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGNKPBPDBKDFND